Skip to main content
Premium Trial:

Request an Annual Quote

Packard Files for Follow-on Offering

NEW YORK, Feb 9 - Packard BioScience said Friday it had filed a statement with the US Securities and Exchange Commission for a follow-on offering of 10 million shares.

Packard of Meriden, Conn., said it would issue three million of the shares, while shareholders, including CEO Emery Olcott and Senior Vice President Richard McKernan, intend to sell an additional seven million shares.

Packard will only receive proceeds from the shares which its sells. The company estimated that it would raise a net $41.25 million from the sale of the shares, which it plans to use for “general corporate purposes.”

The company also expects to generate net proceeds of $120 million to $130 million from the sale of its Canberra division. The sale is expected to close in during the first quarter of this year.

The company had actual cash and cash equivalents of $52.8 million, at the end of September 2000, the last date for which such a figure was available.

Packard’s shares were down 2 3/8, or 16 percent, at 12 1/4 in morning trading.

Me rrill Lynch, Credit Suisse First Boston, J.P. Morgan, Banc of America Securities, and Robert W. Baird are underwriting the offering.

The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.